New Partnership Will Revolutionize Rare Disease Diagnosis through Genomic and Epigenomic Analysis

EpiSign and Geneyx Forge Partnership to Enhance Rare Disease Analysis

In an exciting development for the field of genetic research, EpiSign Inc. and Geneyx Genomex Ltd. have announced a groundbreaking partnership aimed at advancing the integration of genomic and epigenomic analysis specifically for rare disease interpretation. With the combination of EpiSign's expertise in DNA methylation episignature analysis and Geneyx's robust genomic analysis capabilities, the collaboration promises to reshape how laboratories approach complex rare disease cases.

A Comprehensive Solution for Rare Diseases

EpiSign's innovative METRIC platform will now be available to Geneyx's client base. This platform allows laboratories to marry epigenomic evidence with genomic and phenotypic data, creating a unified interpretation workflow that significantly enhances diagnostic accuracy and efficiency.

The METRIC platform simplifies the analysis of disease-linked DNA methylation episignatures across over 300 conditions associated with EpiSign. With the newly introduced METRIC 5-base, this capability expands to accommodate data produced by leading sequencing technologies including Illumina 5-base, PacBio HiFi, and Oxford Nanopore. This integration ensures that laboratories can apply established knowledge in a timely manner, without the need to re-establish foundational knowledge for each new sequencing technology.

Bridging Gaps in Genomic Interpretation

David Yizhar, CEO of Geneyx, emphasizes that the current landscape of genomic interpretation is evolving, moving beyond isolated DNA variants. He asserts that their partnership with EpiSign combines hugely complementary strengths that could redefine the interpretive process for geneticists. By embedding multiple layers of biological evidence within the exploration, the collaboration aims to resolve intricate cases more efficiently and translate data into actionable insights quicker.

EpiSign's co-founder and Chief Scientific Officer, Dr. Bekim Sadikovic, echoed this sentiment, suggesting that the strategic union signals the increasing significance of both genomic and epigenomic data. According to Dr. Sadikovic, advancements in genome sequencing can yield both genetic and epigenetic information concurrently, paving the way for a more holistic interpretation of rare diseases.

Reducing Costs and Diagnostic Delays

Dan Sinai, CEO of EpiSign, highlighted another critical aspect of the collaboration: its potential to address practical challenges in diagnosing rare diseases. By enabling both genomic and epigenomic insights to be gathered from a single assay, laboratories can diminish the need for extensive wet-lab testing, resulting in substantial cost savings. The seamless integration of these data points can also significantly shorten the diagnostic journey for patients and their families, often referred to as the diagnostic odyssey.

A Multi-Omics Future

As both Yizhar and Sinai pointed out, rare disease analysis often requires more than one type of data point for resolution. The goal going forward is to harness the power of multi-omics, giving geneticists the tools to gather all pertinent evidence in a single analytical setting while still maintaining the invaluable expertise of clinical professionals involved in case evaluations.

This partnership also aims to provide laboratories, utilizing short and long-read sequencing workflows, the ability to integrate DNA methylation evidence alongside genomic variants and other relevant biological information during case assessments.

As EpiSign METRIC 5-base becomes accessible for research use globally, both companies are committed to collaborating to broaden integrated genomic and epigenomic workflows across clinical and research facilities worldwide. This partnership sets a precedent that may very well dictate the future of rare disease diagnosis and management, marking a significant leap toward precision medicine in this crucial area.

About EpiSign Inc.

Founded to advance the understanding of rare diseases through cutting-edge technology, EpiSign Inc. specializes in sophisticated DNA methylation analysis geared towards clinical epigenomic applications. Their METRIC platform serves as a crucial tool for automated analysis, aiding laboratories in navigating the intricate landscape of disease-associated DNA methylation.

About Geneyx

Geneyx is a trailblazer in genomic analysis solutions, designed to support clinical laboratories and research entities in navigating the complexities of genomic data. Their platform facilitates various analytical processes, seamlessly integrating genomic, phenotypic, and supplementary biological data, ensuring comprehensive analysis capabilities for geneticists around the world.